Cortina Asset Management LLC Purchased New Holding in Repligen Co. (RGEN)

Cortina Asset Management LLC Purchased New Holding in Repligen Co. (RGEN)

Cortina Asset Management LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN) during the first quarter, Holdings Channel reports. The institutional investor bought 185,077 shares of the biotechnology company’s stock, valued at approximately $6,515,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC increased its stake in Repligen by 8.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,215,810 shares of the biotechnology company’s stock worth $42,797,000 after buying an additional 95,942 shares in the last quarter. State Street Corp increased its stake in Repligen by 12.3% in the fourth quarter. State Street Corp now owns 1,059,196 shares of the biotechnology company’s stock worth $32,643,000 after buying an additional 116,068 shares in the last quarter. Ranger Investment Management L.P. increased its stake in Repligen by 23.8% in the fourth quarter. Ranger Investment Management L.P. now owns 950,881 shares of the biotechnology company’s stock worth $29,306,000 after buying an additional 182,871 shares in the last quarter. Wells Fargo & Company MN increased its stake in Repligen by 10.6% in the first quarter. Wells Fargo & Company MN now owns 767,861 shares of the biotechnology company’s stock worth $27,030,000 after buying an additional 73,852 shares in the last quarter. Finally, William Blair Investment Management LLC increased its stake in Repligen by 4.5% in the first quarter. William Blair Investment Management LLC now owns 706,931 shares of the biotechnology company’s stock worth $24,884,000 after buying an additional 30,198 shares in the last quarter. 94.35% of the stock is owned by institutional investors and hedge funds.

Repligen Co. (NASDAQ RGEN) traded up 1.58% during trading on Friday, hitting $39.98. The company’s stock had a trading volume of 343,230 shares. The firm has a 50 day moving average of $37.55 and a 200 day moving average of $33.44. Repligen Co. has a 12 month low of $21.11 and a 12 month high of $40.31. The firm has a market cap of $1.36 billion, a P/E ratio of 105.49 and a beta of 1.58.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.02. The company had revenue of $30.59 million for the quarter, compared to analysts’ expectations of $29.28 million. Repligen had a return on equity of 10.16% and a net margin of 6.89%. The firm’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 earnings per share. Equities research analysts predict that Repligen Co. will post $0.56 earnings per share for the current year.

A number of analysts have weighed in on RGEN shares. Zacks Investment Research downgraded shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 17th. First Analysis reissued an “equal weight” rating and set a $40.00 target price on shares of Repligen in a research report on Friday, April 21st.

In related news, CFO Jon Snodgres sold 1,909 shares of the company’s stock in a transaction on Friday, March 17th. The stock was sold at an average price of $34.91, for a total value of $66,643.19. Following the sale, the chief financial officer now directly owns 23,789 shares of the company’s stock, valued at $830,473.99. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Howard Benjamin sold 12,216 shares of the company’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $34.62, for a total value of $422,917.92. Following the completion of the sale, the vice president now directly owns 36,124 shares in the company, valued at $1,250,612.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,646 shares of company stock worth $714,898. 2.30% of the stock is owned by insiders.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RGEN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Related posts

Leave a Comment